Current Report Filing (8-k)
September 07 2017 - 7:29AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 7, 2017
Alnylam Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
|
|
Delaware
|
|
001-36407
|
|
77-0602661
|
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
300 Third Street, Cambridge, MA
|
|
02142
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (617)
551-8200
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule
12b-2
of the Securities Exchange Act of
1934(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
On September 7, 2017, Alnylam Pharmaceuticals, Inc. (the
“Company”) announced an update on its fitusiran and givosiran investigational RNAi therapeutic programs. The Company reported a fatal thrombotic event in a patient with hemophilia A without inhibitors in its Phase 2 open label extension
study of fitusiran, an RNAi therapeutic in development for the treatment of hemophilia A and B with or without inhibitors. As a result, the Company has suspended dosing in all ongoing fitusiran studies pending further review of the safety event and
development of a risk mitigation strategy. In addition, the Company reported that it has reached alignment with the U.S. Food and Drug Administration on a Phase 3 study design for givosiran, an RNAi therapeutic in development for the treatment of
acute hepatic porphyrias.
The information in Item 8.01 of this Form
8-K
(including Exhibit 99.1)
shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
|
Item 9.01.
|
Financial Statements and Exhibits
|
The following exhibit relating to Item 8.01 shall be deemed to be furnished, and not
filed:
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Date: September 7, 2017
|
|
|
|
ALNYLAM PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Laurie B. Keating
|
|
|
|
|
|
|
|
Laurie B. Keating
|
|
|
|
|
|
|
|
Senior Vice President, General Counsel and Secretary
|
EXHIBIT INDEX
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2023 to Apr 2024
